

# KELYNIAM GLOBAL, INC.

200 Myrtle Street, 2<sup>nd</sup> Floor, New Britain, CT 06053, 1-800-280-8192, FAX 501-641-2000

# 510(k) Summary Kelyniam Custom Skull Implant

APR 1 4 2011

510(k) Submitter

Kelyniam Global, Inc.

200 Myrtle Street, 2<sup>nd</sup> Floor

New Britain, CT 06053

(800) 280-8192

**Contact Person:** 

James Ketner President/CEO

(800) 280-8192

(860) 832-9331, Ext 223 (501) 641-2000, Fax

Date of Summary:

25 October 2010

**Device Name:** 

Proprietary Name: Kelyniam Custom Skull Implant (CSI)

Common Name: Patient-specific cranial implant

Classification Name: "plate, cranioplasty, preformed, non-

alterable,' a class II device in accordance with 21 CRF §882.5330

Panel:

Neurology

**Product Code:** 

**GXN** 

#### **Device Description:**

The Kelyniam Custom Skull Implant (CSI) is designed individually for each patient to correct defects in cranial bone. The Kelyniam Custom Skull Implant (CSI) is individually sized and shaped implantable prosthetic cranioplasty plates intended to fill defects in a specific patient's cranial skeleton. The implants are composed of PEEK-OPTIMA, and are fabricated using the patient's CT imaging data. The implants are provided with .125" diameter pressure relief holes, equally spaced over the contour of the implant with .625" centerline spacing and a minimum of .500" edge margin. The devices are provided non-sterile for sterilization prior to implantation and are attached to the native bone with commercially available cranioplasty fasteners. This product is a single use device.

### **Indications for use:**

The Kelyniam Custom Skull Patient Specific Cranial implant is intended to replace bony voids in the cranial skeleton.

## **Toxicity**

A series of Limulus Amebocyte Lysate (LAL) test were performed. In these test, the Kelyniam Custom Skull Implants detected endotoxin levels were lower than the minimum requirements for medical devices in contact with cerebrospinal fluid.

### **Substantial Equivalence:**

The Kelyniam Custom Skull Implants (CSI) are substantially equivalent to the Synthes Patient Specific Cranial Implant (PSCI) (K053199), OsteoSymbionics Patient-Specific Cranial Implant (K072601) and KLS Martin Patient Contoured Mesh (K072707). Like these other devices, the Kelyniam Custom Skull Implant (CSI) is manufactured from PEEK or equivalent polymers, sold non-sterile and is customized to each patient.

## **Substantial Equivalence Chart**

	Kelyniam	Synthes Patient	OsteoSymbionics	KLS Martin
	Custom Skull	Specific	Patient-Specific	Patient
	Implant (CSI)	Cranial/Craniofacial	Cranial Implant	Contoured
		Implant (PSCI)	(K072601)	Mesh
		(K053199)		(K072707)
Intended Use	Correction of	Replace bony voids	Correct defects	Replace
r	defects in	in the	in craniofacial	bony voids
	cranial bone	cranial/craniofacial	bone	in the cranial
		skeleton		and/or
				craniofacial
				skeleton
Material	PEEK-OPTIMA	PEEK Optima-LT1	Polymethyl	PEEK (PCM-
	LT1		Methacrylate	P)
		<u></u>	(PMMA)	
Technical	Plate - Custom	Custom sized to	Plate - Custom	Mesh -
Specifications	sized to each	each patient	sized to each	Custom
	patient using		patient	sized to each
	CT data			patient
Sterilization	Non-sterile	Non-sterile	Non-sterile	Non-sterile

# **DEPARTMENT OF HEALTH & HUMAN SERVICES**



Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002

Mr. James Ketner President/CEO/Chairman Kelyniam Global, Inc. 200 Myrtle Street, 2<sup>nd</sup> Floor New Britain, CT 06053

APR 1 4 2011

Re: K103582

Trade Name: Kelyniam Custom Skull Implant (CSI)

Regulation Number: 21 CFR 882.5330

Regulation Name: Preformed Nonalterable Cranioplasty Plate

Regulatory Class: II Product Code: GXN Dated: October 25, 2010 Received: January 25, 2011

Dear Mr. Ketner:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic, Neurological, and Ear,

Nose and Throat Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

## **Indications for Use Statement**

510(k) Number (if known): **以10358**2

Device Name: Kelyniam Custom Skull Implant (CSI)

Indications for Use: Patient Specific Cranial implants are intended for the replacement

of bony voids in the cranial skeleton.

Prescription Use Yes		Over-The-Counter Use No
(Part 21 CFR 801 Subpart D)	AND/OR	(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of Ophthalmic, Neurological and Ear.

Nose and Throat Devices